Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Bullboard Posts
Comment by wexworthon Nov 09, 2020 2:34pm
121 Views
Post# 31864309

RE:RE:Breakaway gap at 30 cents cdn now closed

RE:RE:Breakaway gap at 30 cents cdn now closed
how about they just announce something meaningful from all that time and effort putting together great partnerships and deals. then we don't have to rely on speculation. since we are at the typical 10 year cycle point, we are on average on time to enjoy some big developments. the three big things I want to see are 1) a rodan launch announcement; 2) tinyi definitive agreement, and 3) whatever they are dreaming up on sglt2. moving towards sglt2 next trial phase would be icing on the cake. china is the place for next century biotech so we are uniquely positioned to take advantage of that explosive growth, but that all depends upon whether they can deliver.
Bullboard Posts